Patent · US Active

RNA interference in ocular indications

US10662430B2 · kind B2 · utility

13Cited by

200References

19Claims

0Family size

Assignee

Phio Pharmaceuticals Corp. · US

Inventors

Lyn Libertine · Framingham, US
Anastasia Khvorova · Boulder, US
William Salomon · Worcester, US
Joanne Kamens · Newton, US
Dmitry Samarsky · Berlin, DE
Tod M. Woolf · Sudbury, US
James Cardia · Franklin, US
Pamela Pavco · Longmont, US

Key dates

Filing date	Nov 30, 2018
Grant date	May 26, 2020
Priority date	—
Expiry date	Nov 30, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.